148 related articles for article (PubMed ID: 28717949)
1. Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate
Veronesi F; Di Cesare A; Braun G; Günther L; Morganti G; Rueca F; Petry G; Schaper R; Traversa D
Parasitol Res; 2017 Aug; 116(Suppl 1):65-74. PubMed ID: 28717949
[No Abstract] [Full Text] [Related]
2. Evaluation of the Efficacy and Safety of an Imidacloprid 10 % / Moxidectin 1 % Spot-on Formulation (Advocate
Di Cesare A; Veronesi F; Capelli G; Deuster K; Schaper R; Basano FS; Nazzari R; Paoletti B; Traversa D
Parasitol Res; 2017 Aug; 116(Suppl 1):55-64. PubMed ID: 28717948
[No Abstract] [Full Text] [Related]
3. Evaluation of the Persistent Preventive Efficacy of 2.5 % Moxidectin/10 % Imidacloprid Spot-on (Advocate®, Advantage® Multi) in Dogs Experimentally Infected with Angiostrongylus vasorum.
Böhm C; Petry G; Schmidt H; Raue K; Barthel F; Schaper R
Parasitol Res; 2017 Aug; 116(Suppl 1):1-10. PubMed ID: 28717944
[No Abstract] [Full Text] [Related]
4. A pilot trial evaluating the efficacy of a 10% imidacloprid/2.5% moxidectin spot-on formulation in the treatment of natural nasal capillariosis in dogs.
Veronesi F; Morganti G; Di Cesare A; Schaper R; Traversa D
Vet Parasitol; 2014 Feb; 200(1-2):133-8. PubMed ID: 24365240
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of milbemycin oxime/afoxolaner chewable tablets (NEXGARD SPECTRA
Di Cesare A; Morelli S; Morganti G; Simonato G; Veronesi F; Colombo M; Berlanda M; Lebon W; Gallo M; Beugnet F; Traversa D
Parasit Vectors; 2021 Mar; 14(1):143. PubMed ID: 33676579
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study.
Krieger K; Heine J; Dumont P; Hellmann K
Parasitol Res; 2005 Oct; 97 Suppl 1():S81-S88. PubMed ID: 16228280
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of imidacloprid 10%/moxidectin 1% spot-on formulation in the treatment of feline infection by Capillaria aerophila.
Traversa D; Di Cesare A; Di Giulio E; Castagna G; Schaper R; Braun G; Lohr B; Pampurini F; Milillo P; Strube K
Parasitol Res; 2012 Oct; 111(4):1793-8. PubMed ID: 22782476
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a moxidectin/imidacloprid spot-on formulation (Advocate
Diakou A; Morelli S; Dimzas D; Di Cesare A; Capelli G; Parrinello C; Pollmeier M; Schaper R; Traversa D
Parasit Vectors; 2019 Nov; 12(1):519. PubMed ID: 31685011
[TBL] [Abstract][Full Text] [Related]
9. Assessment of parasitological findings in heartworm-infected beagles treated with Advantage Multi® for dogs (10% imidacloprid + 2.5% moxidectin) and doxycycline.
Savadelis MD; Ohmes CM; Hostetler JA; Settje TL; Zolynas R; Dzimianski MT; Moorhead AR
Parasit Vectors; 2017 May; 10(1):245. PubMed ID: 28526088
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs.
Petry G; Genchi M; Schmidt H; Schaper R; Lawrenz B; Genchi C
Parasitol Res; 2015 Aug; 114 Suppl 1():S131-44. PubMed ID: 26152414
[TBL] [Abstract][Full Text] [Related]
11. Laboratory Evaluation of the Efficacy of 10 % Imidacloprid + 2.5 % Moxidectin Topical Solution (Advantage® Multi, Advocate®) for the Treatment of Dirofilaria immitis Circulating Microfilariae in Dogs.
Bowman DD; Charles SD; Arther RG; Settje T
Parasitol Res; 2015 Aug; 114 Suppl 1():S165-74. PubMed ID: 26152417
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of imidacloprid 10%/moxidectin 2.5% spot on (Advocate®, Advantage Multi®) and doxycycline for the treatment of natural Dirofilaria immitis infections in dogs.
Genchi M; Vismarra A; Lucchetti C; Viglietti A; Crosara S; Gnudi G; Quintavalla C; Schaper R; Kramer L
Vet Parasitol; 2019 Sep; 273():11-16. PubMed ID: 31442887
[TBL] [Abstract][Full Text] [Related]
13. Microfilaricidal efficacy of a single administration of Advocate(®) (Bayer Animal Health) in dogs naturally infected with Dirofilaria immitis or Dirofilaria repens.
Frangipane di Regalbono A; Di Cesare A; Traversa D; Simonato G; Poser H; Danesi P; Furnari C; Russi I; Raele DA; Crisi P; Pampurini F; Pietrobelli M
Vet Parasitol; 2016 Aug; 226():30-4. PubMed ID: 27514879
[TBL] [Abstract][Full Text] [Related]
14. Imidacloprid plus moxidectin topical solution for the prevention of heartworm disease (Dirofiloria immitis) in dogs.
Arther RG; Bowman DD; Slone RL; Travis LE
Parasitol Res; 2005 Oct; 97 Suppl 1():S76-S80. PubMed ID: 16228279
[TBL] [Abstract][Full Text] [Related]
15. Non-Arsenical heartworm adulticidal therapy using topical moxidectin-imidacloprid and doxycycline: A prospective case series.
Ames MK; VanVranken P; Evans C; Atkins CE
Vet Parasitol; 2020 Jun; 282():109099. PubMed ID: 32450463
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a single topical application of Advantage Multi (= Advocate) Topical Solution (10% imidocloprid + 2.5% moxidectin) in the treatment of dogs experimentally infected with Crenosoma vulpis.
Conboy G; Hare J; Charles S; Settje T; Heine J
Parasitol Res; 2009 Aug; 105 Suppl 1():S49-54. PubMed ID: 19575225
[TBL] [Abstract][Full Text] [Related]
17. Treatment of dog thelaziosis caused by Thelazia callipaeda (Spirurida, Thelaziidae) using a topical formulation of imidacloprid 10% and moxidectin 2.5%.
Bianciardi P; Otranto D
Vet Parasitol; 2005 Apr; 129(1-2):89-93. PubMed ID: 15817208
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study.
Segev G; Rojas A; Lavy E; Yaffe M; Aroch I; Baneth G
Parasit Vectors; 2018 Mar; 11(1):127. PubMed ID: 29506575
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of moxidectin 2.5% and imidacloprid 10% in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected dogs.
Otranto D; Colella V; Crescenzo G; Solari Basano F; Nazzari R; Capelli G; Petry G; Schaper R; Pollmeier M; Mallia E; Dantas-Torres F; Lia RP
Vet Parasitol; 2016 Aug; 227():118-21. PubMed ID: 27523947
[TBL] [Abstract][Full Text] [Related]
20. Comments on potential efficacy of monthly administrations of spot-on moxidectin 2.5%/imidacloprid 10% in the simultaneous prevention of major canine filarioses.
Giannelli A; Daugschies A; Dantas-Torres F; Otranto D
Parasitol Res; 2013 Nov; 112(11):3979-80. PubMed ID: 24096604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
